Bambusa Therapeutics IPO: $168.9M Raised at $16, BBTX Opens Down 6.25% on Nasdaq Debut

As of October 30, 2026, Bambusa Therapeutics is a public company: the Boston biopharma priced its upsized IPO at $16.00 a share on October 29, raising $168.9 million in gross proceeds, before debuting on the Nasdaq Global Select Market under ticker BBTX.

Shares opened at $14.88, down 6.25% from the IPO price, on light first-day volume of 292,723 shares, according to IPO-tracking site IPOScoop, which also put the company's market cap at pricing at about $815.7 million.

Bambusa Therapeutics IPO: Key Numbers From Pricing to Debut

Bambusa Therapeutics priced an upsized IPO of 10,555,555 shares at $16.00 on October 29, 2026, raising $168.9 million before debuting as BBTX on Nasdaq the next morning at roughly $815.7 million. Shares then opened down 6.25% at $14.88 in light trading, per IPOScoop.

How we counted: dates and figures as stated in Bambusa Therapeutics' October 29, 2026 pricing release and IPOScoop's October 30, 2026 debut coverage; 6 milestones from incorporation to expected closing, as of October 30, 2026.

How Did BBTX Perform on Its Nasdaq Debut?

BBTX did not get the first-day pop that some 2026 biotech debuts have seen. Shares opened at $14.88 at 11:31 a.m. EDT on October 30, 2026 — down $1.12, or 6.25%, from the $16.00 IPO price — on light volume of 292,723 shares, according to IPOScoop. The underwriters — BofA Securities, Evercore ISI, UBS Investment Bank, and Cantor — still have a 30-day option to buy up to 1,583,333 additional shares at the IPO price, which could add to gross proceeds if exercised, per the company's pricing announcement. The deal is expected to close on November 2, 2026.

What Does Bambusa Therapeutics Do?

Bambusa Therapeutics is a clinical-stage biopharmaceutical company based in Boston that develops long-acting, precision bispecific antibodies for immunology and inflammation, using high-concentration subcutaneous delivery, according to the company's IPO pricing release. Its lead candidate, BBT001, targets IL-4Rα and IL-31 and is in a Phase 1 trial for atopic dermatitis and other inflammatory skin diseases; a second candidate, BBT002, targets IL-4Rα and IL-5 for Type 2 inflammatory disorders including COPD, with trials underway in the U.S., Europe, and China, per IPOScoop. Two earlier-stage programs, BBT003 and BBT004, target inflammatory bowel disease and autoantibody-driven autoimmune disease and remain preclinical.

The company, incorporated in Delaware on March 14, 2024, acquired its lead assets from a BioNTech subsidiary formerly known as Biotheus, and reported a net loss of $48.7 million for the 12 months ended June 30, 2026, per IPOScoop. It has no approved products and no disclosed product revenue.

Bambusa's platform is built around bispecific antibodies engineered for high-concentration subcutaneous delivery, meaning each antibody is designed to bind two separate inflammatory targets at once and be injected rather than infused, according to the company's pricing release. IPOScoop reports that a subcutaneous, dose-ranging Phase 2b trial of BBT001 is planned, with study start-up activities expected to begin by the end of 2026, and that the preclinical BBT003 and BBT004 programs are each targeted to enter Phase 1 by the end of 2026 and 2027, respectively.

Bambusa's Funding History Before the IPO

Bambusa Therapeutics closed an oversubscribed Series A of approximately $90 million on February 14, 2025, led by new investor RA Capital Management, with new investors Janus Henderson Investors, Redmile Group, Invus, and ADAR1 Capital Management joining alongside existing backers, according to the company's PR Newswire announcement. RA Capital partner Derek DiRocco joined Bambusa's board as part of that round, and RA Capital remained a principal shareholder heading into the IPO, per IPOScoop. Bambusa's founder and chief executive is Shanshan Xu, M.D., Ph.D.

Who Underwrote Bambusa's IPO?

BofA Securities, Evercore ISI, UBS Investment Bank, and Cantor served as joint book-running managers on Bambusa's offering, according to the company's pricing announcement. That same four-bank syndicate backed the deal through an upsize from 9.38 million to 10,555,555 shares while keeping the price at the midpoint of the marketed range, which IPOScoop frames as evidence the book was genuinely oversubscribed rather than priced down to get the deal done. Pricing and the registration statement both became effective on October 29, 2026, ahead of the October 30 Nasdaq debut and the expected November 2 closing.

Where Bambusa's IPO Fits in the 2026 Biotech Rebound

Bambusa priced toward the smaller end of a busy 2026 US biotech IPO class that BioSpace tracks as a "cautiously optimistic" rebound after 2025 produced only eight biopharma IPOs, the fewest of the post-pandemic era. FTI Consulting's Michael Rachlin told BioSpace the market is entering "a more discerning IPO marketplace" that favors companies with later-stage assets — a read consistent with Bambusa pricing below several 2026 peers with more advanced pipelines.

BioSpace's tracker shows the 2026 class opened with Aktis Oncology's $318 million raise on January 9 and grew from there: Eikon Therapeutics upsized to $381 million on February 5, and Generate:Biomedicines raised $400 million on February 27 at $16.00 a share — the same per-share price Bambusa priced at eight months later. Parabilis Medicines closed the largest deal tracked, $670 million on June 10 at $20.00 a share, per BioSpace, while Seaport Therapeutics ($254.9 million, closing April 30) and Avalyn Pharma ($300 million, April 30) priced on the same day as each other earlier in the year, a pairing similar to Bambusa and Aspen Neuroscience's same-week debuts in late October.

How we counted: US biotech IPOs that priced in 2026 and appear on BioSpace's tracker, ranked by gross proceeds, as of October 30, 2026; Bambusa's figure from its own pricing release.

What the headline misses

$168.9 million is gross proceeds before underwriting discounts and offering expenses, and that figure could still grow if underwriters exercise their option on the remaining 1,583,333 shares. The $815.7 million market cap IPOScoop cites is a pricing-day snapshot, not the stock's current value — and BBTX's actual first trade came in below that mark, opening 6.25% under the IPO price rather than popping.

The business itself remains purely pipeline-stage: BBT001 is only in Phase 1 testing, BBT002 is in earlier-stage trials, and BBT003 and BBT004 are preclinical. Bambusa has no approved products, no disclosed revenue, and a $48.7 million net loss for the year ended June 30, 2026 — public investors are pricing a research platform and early clinical data, not a commercial business, and years of further trials and capital likely stand between this IPO and any potential product revenue.

A down debut on light volume is also not, by itself, a verdict on the company: per IPOScoop, only 292,723 BBTX shares changed hands in the opening stretch, a small fraction of the 10,555,555 shares in the deal, which limits how much the first print says about sustained investor demand. The more informative test is whether BofA Securities and the rest of the syndicate exercise their option on the remaining 1,583,333 shares by the November 2 closing, and how BBT001's Phase 1 data reads once it is available, given that the roughly $815.7 million pricing-day market cap was assigned almost entirely on pipeline promise.